RADT for GAS (cohort 1) | Throat culture (cohort 2) | |||||||
---|---|---|---|---|---|---|---|---|
Positive n = 9170 | Negative n = 4611 | All n = 13,781 | S. pyogenes1 n = 201 | S. dysgalactiae ssp. equisimilis1 n = 190 | F. necrophorum1,2 n = 95 | Negative n = 905 | All2 n = 1 370 | |
Female, n (%) | 5 068 (55) | 2 585 (56) | 7 653 (56) | 111 (55) | 119 (63) | 57 (60) | 509 (56) | 785 (57) |
Age, years, median (IQR) | 19 (7–36) | 23 (16–38) | 21 (9–37) | 27 (12–38) | 20 (17–29) | 21 (17–26) | 23 (17–38) | 23 (17–36) |
Age 0–14, n (%) | 4 056 (44) | 1 024 (22) | 5 080 (37) | 64 (32) | 24 (13) | 2 (2.1) | 146 (16) | 236 (17) |
Age 15–29, n (%) | 1 882 (21) | 1 928 (42) | 3 810 (28) | 45 (22) | 119 (63) | 75 (79) | 422 (47) | 646 (47) |
Age 30 + , n (%) | 3 232 (35) | 1 659 (36) | 4 891 (35) | 92 (46) | 47 (25) | 18 (19) | 337 (37) | 488 (36) |
RADT performed (cohort 2), n (%) | 139 (69) | 154 (81) | 73 (77) | 660 (73) | 1 011 (74) | |||
RADT positive/all RADT, n (%) | 104 (75) | 6 (3.9) | 6 (8.2) | 83 (9.2) | 196 (19) | |||
Antibiotic treatment3, n (%) | 8 751 (95) | 1 997 (43) | 10 748 (78) | 151 (75) | 97 (51) | 52 (55) | 429 (47) | 717 (52) |
Penicillin V, n (% of treated) | 7 894 (90) | 1 630 (82) | 9524 (89) | 106 (70) | 73 (75) | 34 (65) | 324 (76) | 527 (74) |
Clindamycin, n (% of treated) | 339 (3.9) | 181 (9.1) | 520 (4.8) | 21 (14) | 14 (14) | 17 (33) | 73 (17) | 123 (17) |
Cefadroxil, n (% of treated) | 345 (3.9) | 116 (5.8) | 461 (4.3) | 20 (13) | 8 (8.2) | 0 | 24 (5.6) | 52 (7.3) |
Other, n (% of treated) | 173 (2.0) | 70 (3.5) | 243 (2.3) | 4 (2.6) | 2 (2.1) | 1 (1.9) | 8 (1.9) | 15 (2.1) |